Related Experiment Videos

[Economic study of carvedilol in heart failure. A cost effectiveness study in France]

P Lévy1, J L Dubois-Randé, A Cohen-Solal

  • 1LEGOS, université Paris-IX Dauphine, place du Maréchal-de-Lattre-de-Tassigny, 75775 Paris.

Archives Des Maladies Du Coeur Et Des Vaisseaux
|March 27, 2001
PubMed

Insights

Carvedilol significantly reduces mortality and hospital admissions in heart failure patients. This heart failure treatment offers economic advantages, proving cost-effective with substantial savings in hospital expenses.

Area of Science:

  • Cardiology
  • Pharmacoeconomics
  • Clinical Trials

Background:

  • Heart failure (HF) poses a significant mortality and morbidity burden.
  • Standard bitherapy, with or without digitalis, is the current treatment for HF.
  • Carvedilol's efficacy in reducing mortality and hospital admissions in HF patients has been demonstrated in Phase III trials.

Purpose of the Study:

  • To evaluate the cost-effectiveness of Carvedilol in the French healthcare system.
  • To assess the economic impact of incorporating Carvedilol into standard HF treatment.
  • To determine the cost per life saved and per additional year of life expectancy.

Main Methods:

  • A cost-effectiveness analysis was conducted, extrapolating Phase III trial data to the French population.
  • Direct medical costs (drugs, hospital admissions) were compared between strategies with and without Carvedilol.
  • Hospital expenses were estimated using H.M.G. (Hospitalization-at-Home Management Group) at 1997-1998 values.

Main Results:

  • The Carvedilol group incurred an increased cost of 767 FF per patient but achieved a 50% reduction in mortality.
  • The cost-effectiveness was calculated at 17,040 FF per life saved and 2,130 FF per additional year of life expectancy.
  • Analysis of AP-HP (Assistance Publique – Hôpitaux de Paris) data indicated a 4,425 FF reduction in hospital expenses, classifying Carvedilol as a cost-saving strategy.

Conclusions:

  • Carvedilol is a cost-effective addition to standard heart failure therapy, significantly reducing mortality and hospitalizations.
  • The drug presents a favorable economic profile, leading to overall cost savings within the healthcare system.
  • Carvedilol offers a valuable therapeutic and economic benefit for patients with cardiac failure.

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...